

1 **Pre-vaccination transcriptomic profiles of immune responders to the MUC1**
2 **peptide vaccine for colon cancer prevention**

3
4 Cheryl M. Cameron^{1†}, Vineet Raghu^{2,3†}, Brian Richardson^{1,4†}, Leah L. Zagore⁴,
5 Banumathi Tamilselvan¹, Jackelyn Golden⁴, Michael Cartwright⁴, Robert E. Schoen⁵,
6 Olivera J. Finn^{6*}, Panayiotis V. Benos^{7,8*}, Mark J. Cameron^{4*}

- 7
8
9 ¹ Department of Nutrition, Case Western Reserve University, Cleveland, OH
10 ² Department of Computer Science, University of Pittsburgh, Pittsburgh, PA
11 ³ Massachusetts General Hospital, Harvard Medical School, Cambridge, MA
12 ⁴ Department of Population and Quantitative Health Sciences, Case Western
13 Reserve University, Cleveland, OH
14 ⁵ Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh,
15 Pittsburgh, PA
16 ⁶ Department of Immunology, University of Pittsburgh, Pittsburgh, PA
17 ⁷ Department of Epidemiology, University of Florida, Gainesville, FL
18 ⁸ Department of Computational and Systems Biology, University of Pittsburgh,
19 Pittsburgh, PA

20
21 † Contributed equally
22 * Co-corresponding authors

23
24
25 **Keywords:** colon cancer, colorectal adenoma, cancer vaccine, transcriptomics, MUC1,
26 serological response
27

28 **Abstract**

29 Self-antigens abnormally expressed on tumors, such as MUC1, have been targeted by
30 therapeutic cancer vaccines. We recently assessed in two clinical trials in a preventative
31 setting whether immunity induced with a MUC1 peptide vaccine could reduce high colon
32 cancer risk in individuals with a history of premalignant colon adenomas. In both trials,
33 there were immune responders and non-responders to the vaccine. Here we used PBMC
34 pre-vaccination and 2 weeks after the first vaccine of responders and non-responders
35 selected from both trials to identify early biomarkers of immune response involved in long-
36 term memory generation and prevention of adenoma recurrence. We performed flow
37 cytometry, phosflow, and differential gene expression analyses on PBMCs collected from
38 MUC1 vaccine responders and non-responders pre-vaccination and two weeks after the
39 first of three vaccine doses. MUC1 vaccine responders had higher frequencies of CD4
40 cells pre-vaccination, increased expression of CD40L on CD8 and CD4 T-cells, and a
41 greater increase in ICOS expression on CD8 T-cells. Differential gene expression
42 analysis revealed that iCOSL, PI3K AKT MTOR, and B-cell signaling pathways are
43 activated early in response to the MUC1 vaccine. We identified six specific transcripts
44 involved in elevated antigen presentation, B-cell activation, and NF- κ B1 activation that
45 were directly linked to finding antibody response at week 12. Finally, a model using these
46 transcripts was able to predict non-responders with accuracy. These findings suggest that
47 individuals who can be predicted to respond to the MUC1 vaccine, and potentially other
48 vaccines, have greater readiness in all immune compartments to present and respond to
49 antigens. Predictive biomarkers of MUC1 vaccine response may lead to more effective
50 vaccines tailored to individuals with high risk for cancer but with varying immune fitness.

51 **Introduction**

52 Self-antigens abnormally expressed in tumors, known as non-viral cancer-associated
53 antigens, have been extensively tested over the last three decades as antigens in
54 therapeutic cancer vaccines (1-3). In preclinical studies, an immune response to these
55 antigens can prevent cancer growth without causing toxicity. In humans, preexisting
56 immunity to some such antigens correlates with better disease outcome or reduced risk
57 of cancer recurrence (4). Nevertheless, therapeutic vaccines utilizing these antigens
58 have had low immunogenicity and no clinical efficacy. This has been attributed to the
59 presence of many immunosuppressive influences in the tumor microenvironment (5, 6).
60 MUC1 is a cancer-associated antigen that has been effective as a vaccine in preclinical
61 animal models but showed limited immunogenicity and efficacy as a therapeutic vaccine
62 in clinical trials in colon, breast, pancreas, prostate and lung cancer (7-11). Hypothesizing
63 that the major difference between the outcome of the vaccine in preclinical models and
64 clinical trials is the high level of immune suppression in cancer patients, we began to
65 develop models and MUC1 vaccines for cancer prevention in patients at risk; before
66 immune suppression develops. As MUC1 is expressed on early premalignant lesions as
67 well as cancer, we chose to study immunogenicity, safety and potential efficacy of this
68 vaccine in the preventative setting in individuals with a history of colonic polyps that
69 increases their risk of colon cancer (12).

70 From 2008 to 2012, we conducted a single arm trial (NCT-007773097) (13) in 41
71 individuals. Forty-three percent (43%) of vaccinated participants responded to the vaccine
72 as measured by production of anti-MUC1 IgG at week 12 post vaccination (vaccine
73 responders), and 57% did not respond (vaccine non-responders). From 2015-2020, we

74 conducted the second study, a randomized, double-blind placebo-controlled multi-center
75 efficacy trial of the same MUC1 vaccine in the setting of newly diagnosed advanced
76 adenomas in 110 individuals (NCT-02134925) (14). Twenty-seven percent (27%) of the
77 vaccinated participants responded to the vaccine. In addition to the immune response, in
78 this trial we evaluated adenoma recurrence by follow-up colonoscopy ≥ 1 year from the
79 start of vaccination. In vaccine responders, adenoma recurrence was reduced by 38%
80 compared to non-responders and placebo controls. Predictable factors such as gender,
81 age, and HLA-type were not significantly different between vaccine responders and non-
82 responders. It became important to understand why some individuals mounted a
83 potentially protective immune response, while others did not, having the same diagnosis.

84 In this study, we analyzed PBMC samples collected from both trials at baseline (pre-
85 vaccination) and 2 weeks post-first of 3 vaccines (week 0, week 2 and week 10) from
86 vaccine responders and non-responders and identified comprehensive gene and
87 pathway biomarkers related to vaccine response. We discovered that several key T- and
88 B-cell cellular proliferation and stress pathways were enriched in responders, while
89 oxidative phosphorylation and DNA damage response and repair pathways were
90 enriched in non-responders. Responders had higher frequencies of CD4 cells at baseline,
91 with higher activation and/or costimulatory signaling in CD8 and CD4 T-cells from
92 baseline to week 2 in CD8 T-cells. Phosflow analysis revealed enhanced phosphorylation
93 of B-cell signaling molecules and T-cell help targets in responders at baseline and a
94 significant increase in NF κ B phosphorylation in B-cells at week 2. Lastly, we applied
95 graphical modeling approaches (15-17) to this data and built a regression model to

96 discriminate future responders and non-responders via their predicted and actual IgG
97 response at week 12.

98 **Materials and Methods**

99 **PBMC collection**

100 PBMC samples from patients with a history of, or with newly diagnosed, advanced colonic
101 adenoma and at high risk for colon cancer were collected as part of two clinical trials of a
102 MUC1 vaccine registered at clinicaltrials.gov (NCT-007773097, NCT-02134925) (13, 14).
103 The ethics committee/IRB of the following institutions gave ethical approval for this work:
104 Mayo Clinic, Rochester MN; Kansas City Veterans Affairs Medical Center, Kansas City,
105 KS; University of Pittsburgh Medical Center, Pittsburgh PA; University of Puerto Rico,
106 San Juan PR; Thomas Jefferson University Hospital, Philadelphia PA; and
107 Massachusetts General Hospital, Boston MA. All participants provided written informed
108 consent. Blood samples were processed within 24 hours by the same individual, using
109 the same protocol. Heparinized blood was layered on lymphocyte separation medium
110 (MPbio) and centrifuged at 800 g for 10 min with lowest acceleration and deceleration
111 speed. PBMC were collected from the interphase, washed twice, resuspended in 80%
112 human serum and 20% DMSO, and stored in liquid nitrogen.

113

114 **RNA-Seq**

115 PBMC samples were thawed, pelleted, and lysed in 350 uL of RLT with beta-
116 mercaptoethanol. RNA was isolated using the RNeasy Mini kit (Qiagen). RNA quality was
117 assessed with the Fragment Analyzer (Agilent) and its Standard Sensitivity RNA kit. Total
118 RNA was normalized to 100 ng prior to random hexamer priming and libraries generated

119 by the TruSeq Stranded Total RNA – Globin kit (Illumina). The resulting libraries were
120 assessed on the Fragment Analyzer (Agilent) with the High Sense Large Fragment kit
121 and quantified using a Qubit 3.0 fluorometer (Life Technologies. Medium depth
122 sequencing (>30 million reads per sample) was performed with a HiSeq 2500 (Illumina)
123 on a High Output, 125 base pair, Paired End run.

124

125 **Bioinformatic analysis**

126 Raw demultiplexed fastq paired end read files were trimmed of adapters and filtered using
127 the program skewer (18), discarding those with an average phred quality score <30 or a
128 length <36. Trimmed reads were aligned to human reference genome GRCh38 using
129 HISAT2(19) and sorted using SAMtools (20). Aligned reads were counted and assigned
130 to gene meta-features using the program featureCounts (21) as part of the Subread
131 package. Quality control, normalization and analysis were performed in R, using an in-
132 house pipeline utilizing the limma-trend method for differential gene expression testing
133 and the GSEA (22) library for gene set sample enrichment. Final differential gene
134 expression lists were filtered to remove non-coding RNAs as well as LOC features. The
135 datasets for this study can be found in the Gene Expression Omnibus (GEO) public
136 database with the accession number pending.

137

138 **Flow cytometric analysis**

139 For immune cell phenotyping and assessment of intracellular levels of bcl2, and
140 phosphorylation of STAT3, erk1/2, NF-kB and MTORC targets, cells were first stained
141 with Live/Dead Aqua (Invitrogen) followed by cocktails of monoclonal antibodies

142 recognizing the following cell surface markers: CD4, CD8, CD45RA, CD27, CCR7,
143 CD152, CD86, CD275, CD11c, CD56, CD16, CD19, CD3, HLA-DR, CD14, CD40, and
144 CD11b. Cells were washed, fixed and permeabilized, then stained with antibodies specific
145 for the following intracellular proteins: NFkB p65, erk1/2 (pT202/pY204), STAT3 (pY705),
146 Akt1, pS6 (S235/236 & S240) and p4E-BP1 (T36/46). Cells were washed and fixed and
147 events were collected on a BD ARIA-SORP instrument. A 15-minute incubation at 37C
148 with recombinant human IL-6 (100ng/mL) (BD Pharmingen) was performed to induce
149 NFkB signaling. After washing, cells were resuspended in staining buffer and sorted on
150 an ARIA-SORP. Data was analyzed using FlowJo software (TreeStar).

151

152 **Predictive model for post-vaccination immune response**

153 A detailed explanation of computational model development and evaluation can be found
154 in the supplemental methods. Briefly, a LASSO logistic regression (23) was used to
155 develop a prediction model for a binary outcome of response defined by the clinical trial
156 endpoint (≥ 2 -fold increase in IgG from baseline to week 12), using transcriptomic data
157 measured two-weeks post-vaccination (Week 2 data). A Mixed Graphical Models (MGM)
158 algorithm was used to infer a unidirectional graphical model followed by FCI-MAX to
159 determine direction. All statistical analysis was performed in R.

160

161 **Statistics**

162 Unless otherwise indicated, the Student's t-test was used, with $p \leq 0.05$ chosen as the
163 level of significance.

164

165 **Results**

166 **Vaccine responders and non-responders show differential gene expression in**
167 **PBMCs pre-vaccination**

168 Next-generation RNA-seq analysis was performed on PBMCs from 46 participants of the
169 two trials, conducted in the same setting of advanced adenoma and with the identical
170 vaccine and vaccination protocol. The vaccine, composed of 100 μ g of MUC1 peptide plus
171 the polyI:CLC adjuvant Hiltonol[®], was administered at week 0, 2, 10 and 52. We assayed
172 PBMC samples collected at the time of the first injection (baseline) and 2 weeks later, at
173 the time of the second injection in order to be able to define preexisting (at baseline) and
174 early post-vaccination (week 2) signatures of response to MUC1 vaccination. Vaccine
175 responders (R, n=13) in both trials were defined as having anti-MUC1 IgG levels at week
176 12 (after all three injections) at least two-fold higher than baseline. For some of our
177 analyses we also classified responders by antibody levels into high responders (HR, anti-
178 MUC1 IgG OD450 at 1:80 plasma dilution ≥ 0.4), low responders (LR, OD450 at 1:80
179 plasma dilution < 0.4), and non-responders (NR) (no difference from baseline).

180 RNA-seq performed on PBMCs collected immediately pre-vaccination (baseline)
181 revealed a total of 2,321 genes that were differentially expressed between all responders
182 and all non-responders at baseline (Fig 1A). Within these genes, 1,337 showed increased
183 transcript levels and 984 showed decreased levels. Among the top 50 differentially
184 expressed genes by p-value (Fig 1B), 47 genes were upregulated in responders
185 compared to non-responders. The upregulated genes were involved in transcriptional and
186 epigenetic regulation, including multiple subunits of the SWI/SNF chromatin remodeling
187 complex (ARID1A, ARID1B, and SMARCC2), as well as NCOA6, a multifunctional

188 transcriptional coactivator and component of the Set1-like H3K4-methyltransferase
189 complex ASCOM, all of which have been shown to play a role in the pathogenesis of
190 cancer (24). Additional cancer-relevant transcriptional regulators higher in responders
191 before vaccination include SP2, NFYC, AKNA, MYPOP, and ZNF652. CUX1 is a subunit
192 of the NF- μ NR repressor that binds to the matrix attachment regions of the
193 immunoglobulin heavy chain enhancer and the TCR enhancer. The epigenetic regulator
194 HCFC1 tethers Set and Sin3 histone modifying complexes together and was also higher
195 in responders at baseline (25). We observed an increase in TRAPPC9, an activator of
196 NF κ B, and FAM168A, which is involved in the PI3K/AKT/NF κ B signaling pathway.
197 RRAGA was one of 3 downregulated genes among the top differentially expressed genes
198 in responders and plays a role in regulating the mTORC1 complex (26). The presence of
199 transcriptional and epigenetic regulators within the list of upregulated genes could explain
200 the large number of significant changes in steady-state RNA levels we observed and
201 suggests a differing global transcriptional program between responders and non-
202 responders before vaccination. As these upstream regulators have the potential to
203 broadly remodel the transcriptome, they may represent potent therapeutic targets.

204 **Vaccine responders and non-responders show differences in gene expression in** 205 **PBMCs at week 2 post-vaccination**

206 At two weeks post-first injection, we found 1,887 genes differentially expressed in
207 responders vs. non-responders, 934 genes upregulated and 953 genes downregulated
208 (Fig 1C). The top 50 genes arranged by p-value are shown in Figure 1D. Among the
209 upregulated genes are several cancer-related transcriptional regulators including PPAR δ

210 (27) and HMGA1 (28), key regulators of lipid pathways (29), transcription elongation
211 factor SPT6 (SUPT6H), SOAT2, an enzyme involved in lipoprotein and cholesterol
212 regulation, and GPD1, an enzyme that plays a key role in lipid metabolism, are also
213 upregulated in responders. Among the downregulated cancer-related genes we found
214 five involved in mitosis and G2/M DNA replication checkpoint, the kinesin-like proteins
215 KIF11 and KIF15 (30), centromere/centrosome proteins CENPF and CEP55 (31), and the
216 cell cycle regulator protein DLGAP5 (32). Importantly, CEP55 and DLGAP5 are key
217 predictors of antibody response in our graphical model discussed below.

218 We then performed double contrast analysis of the genes that were significantly
219 differentially changed from baseline to week 2 in the responders vs. non-responders (Fig
220 1E). The top 50 genes by p-value (Fig 1F) are enriched in immune-related genes. IFNL1
221 is upregulated in contrast to CD38 and IL12RB2, which are downregulated in responders.
222 Again, selective upregulation of transcriptional and epigenetic regulators in responders is
223 evident; examples include PRDM5, ZNF230, ZCCHC9, ZKSCAN4, and the epigenetic
224 regulator ALKBH3, which demethylates DNA and RNA in cancer cells (33).

225 **ICOS/ICOSL signaling is differentially associated with response to the MUC1** 226 **vaccine**

227 We performed gene set variation analysis (GSVA) of the baseline gene expression data
228 to identify biological pathways regulating the response to vaccination. Vaccine
229 responders displayed significant upregulation of genes involved in the ICOS-ICOSL
230 pathway in T-helper Cells signaling pathway, with increased expression of multiple genes
231 both at baseline and week 2 post-vaccination (Fig 2A and 2B, respectively). At baseline,

232 responders expressed higher levels of ICOSL, IL2RB, and CD4 coreceptor genes, while
233 at week 2 post-vaccination higher levels of the downstream NFKB pathway genes
234 including NFKB2, RELB and RELA were evident.

235 By flow cytometry, we determined that higher frequencies of CD4 T-cells were present in
236 responders at baseline, potentially related to enhanced ICOSL signaling (Fig 2C). We
237 also detected differences in expression levels of key proteins in this pathway. Higher
238 levels of expression of CD40L were evident in CD4 and CD8 cells (Fig 2D and 2E
239 respectively). Greater increases in ICOS expression were detected post-vaccination
240 in CD8 T-cells of responders. (Fig 2F).

241 **mTOR signaling is upregulated in responders to MUC1 vaccination**

242 As many components of the ICOS/ICOSL pathway were significantly higher in the
243 responders vs. non-responders, we focused on differences in the mTOR signaling
244 pathway which lies directly downstream of ICOS/ICOSL engagement. Top enriched
245 pathways in high responders vs. non-responder comparisons included PI3K/AKT/MTOR
246 signaling, WNT/beta-catenin signaling and hedgehog signaling (Fig 3A). In contrast, the
247 Myc targets V1 pathway and DNA repair were negatively associated in high responders.

248 To validate enhanced mTOR signaling in responders, we developed a phospho-based
249 panel of antibodies (see Materials and Methods) to measure the phosphorylation levels
250 of RPS6, a commonly used readout of mTORC1 activity. There was a greater increase in
251 RPS6 phosphorylation in CD4 and CD8 T-cells, B-cells (CD19), and monocytes (CD14)
252 of responders, an observation validating our finding at the phosphoprotein level (Fig 3B).

253 We also performed intracellular staining targeting the phosphorylated AKT1 kinase
254 upstream of the MTORC1 signaling complex. Similarly, we found a greater increase in
255 AKT1 phosphorylation in responders compared to non-responders.

256 **B-cell signaling and enhanced antigen presentation signatures are positively**
257 **associated with response to MUC1 vaccination**

258 As ICOS/ICOSL-mediated signaling promotes fitness of the T lymphocyte compartment,
259 we hypothesized that signaling from the T-cells to the B-cell and APC compartment was
260 also differentially induced. Pathway enrichment analysis of the transcriptomic data
261 revealed significant enrichment of B-Cell Receptor Signaling and PI3K Signaling in B
262 Lymphocytes pathways at baseline (Fig 4A and 4B) and NFkB and CD40 Signaling
263 pathways at baseline and at week 2 post-vaccination (Fig 4C and 4D). CD40 receptor
264 engagement on the surface of antigen presenting cells, such as B-cells, leads to
265 activation of NFkB signaling and enhanced cellular survival and function. Notably, multiple
266 signaling component genes (MAP kinases and Jak3) are significantly upregulated in
267 responders at baseline, followed by upregulation of additional signaling molecules at
268 week two (TRAF1, TRAF3, NFKB1, NFKB2, RELA and RELB).

269 We validated increased expression of CD40 and HLA-DR on B-cells (CD19+) in
270 responders (Fig 4E) using flow cytometric analyses. We used an intracellular phosflow
271 panel to detect phosphorylation of the p65 subunit of NFkB. We found increased IL6-
272 induced NFkB signaling via phosphorylation of p65 in T-cells, HLA-DR+ non-B/non-DC
273 APCs and B-cells of responders (Fig 4F), and B-cells of high responders expressing
274 significantly higher levels of HLADR compared to non-responders (Fig 4E).

275 Finally, we performed gene set variation analysis using the Nakaya et al. vaccine
276 immunogenicity pathway database (34) and determined that a plasmacytoid dendritic cell
277 (DC) signature was already enriched in the PBMCs of responders at baseline (Fig 5A)
278 and further enriched at week 2 post-vaccination (Fig 5B). Vaccine responders showed
279 increased HLA-DR levels on DCs (CD3-, CD19-, HLA-DR+, CD11c+) at baseline (Fig
280 5C). Responders also showed a greater relative change in CD86 and CD40 expression
281 from baseline to two weeks (Fig 5D-E). Altogether, these results indicate that additional
282 signatures of enhanced antigen presentation are associated with enhanced response to
283 MUC1 vaccination.

284 **Six differentially expressed transcripts 2 weeks post-vaccination predict week 12** 285 **IgG response to the MUC1 vaccine**

286 Based on evidence of key differences in cell populations and molecular pathways
287 between responders and non-responders at baseline and post-vaccination, we
288 hypothesized that some differentially expressed genes may be useful for patient selection
289 and outcome prediction. We tested this hypothesis by applying LASSO regression and
290 MGM-FCI-MAX (17), a graphical modeling algorithm, to 7,968 transcripts meeting a
291 minimal variance threshold. We first performed a cross-validation experiment (see
292 Supplemental Methods) to assess the ability to predict antibody response to the vaccine
293 at week 12, using the transcriptomic signatures at week 2 post-vaccination. Our model
294 achieved an area under the receiver operating characteristic curve (AUROC) value of
295 0.741 to predict response vs. non-response (Fig 6A). At a predicted probability threshold
296 of 0.5, the model achieved a sensitivity of 91.7% (22 predicted responders / 24 true

297 responders) and a specificity of 36.8% (7 predicted non-responders / 19 true non-
298 responders). Predicted response odds were correlated with the magnitude of antibody
299 titer at week 12 ($R^2 = 0.209$, $p < 0.001$) (Fig 6B), and with the ratio of IgG titer at week 12
300 versus baseline ($R^2 = 0.147$, $p = 0.015$).

301 Next, we used graphical models to determine the variables directly linked to week 12
302 antibody titer and distinguish them from simple correlates. We produced a full model with
303 all genes selected in the previous cross-validation experiments, which were learned using
304 the entire week 2 dataset (Fig 6C). Finally, we identified 6 genes that are directly linked
305 to week 12 antibody titer: RP11.81H14.2, CEP55, and TNFSF14 (negatively associated)
306 and C22orf29, DDX12P, and HLA-DQA2 (positively associated) (Fig 6D). The role of
307 these transcripts and how they may contribute to the induction of immune response and
308 vaccine efficacy (discussed below) warrants further investigation.

309 **Discussion**

310 Therapeutic cancer vaccines, tested in numerous clinical trials over several decades,
311 failed to realize the promise generated by the discovery of tumor antigens capable of
312 eliciting humoral and cellular immunity. In most cases, vaccines administered after
313 primary tumor removal failed to boost anti-tumor immunity and prevent tumor recurrence.
314 Ultimately, a greater understanding of the many immunosuppressive forces in the tumor
315 microenvironment helped to explain the reduced efficacy of therapeutic vaccines. These
316 discoveries support preventative vaccines as an alternative approach to cancer
317 vaccination to reduce cancer risk and incidence as they could be applied in the absence
318 of cancer and cancer-induced immunosuppression. The two clinical trials from which we

319 derived the PBMCs, applied this preventative approach by vaccinating individuals without
320 cancer but at high risk for colon cancer due to advanced colonic adenoma diagnosis (13,
321 14). We expected a vaccine response from most individuals, measured by the production
322 of anti-MUC1 IgG antibodies. It came as a surprise, therefore, that the majority did not
323 respond. However, those who responded had high levels of anti-MUC1 antibodies and
324 established a long-lasting memory response, showing that the vaccine was capable of
325 inducing immunity and response was determined by the individuals receiving the vaccine.
326 Mechanisms underlying this variable response to an apparently efficacious vaccine were
327 not clear.

328 To address this major knowledge gap with an unbiased approach, we performed RNA-
329 seq on total PBMCs from participants in the two MUC1 peptide vaccine trials to identify
330 genes and pathways differentially regulated at baseline as well as post-vaccination in the
331 participants that responded versus those that failed to respond to the vaccine. The
332 analysis revealed that vaccine responders at baseline exhibited an enrichment of key
333 pathways governing survival and proliferation in immune cells, such as mTOR and NFKB
334 signaling, as well as increased frequencies of CD4 and CD8 T-cells. There were more
335 memory CD8 T-cells at baseline and week 2 (post MUC1 vaccine) in responders (Fig 2A
336 and 2E). Responders also had more CD4 T-cells at baseline and higher frequencies of
337 memory CD4 T-cells at week 2 (Fig 2A, 2C, 2D). Other immune compartments appeared
338 to differ in favor of responders with higher levels of BCL2 expression at baseline in CD14+
339 and greater increases in BCL2 expression at week 2 post-vaccination (data not shown).
340 The control of DC longevity by the regulation of BCL2 directly impacts immune responses.

341 Higher levels of BCL2 suggest enhanced survival in the myeloid compartment and
342 consequently better antigen presentation.

343 The differentially expressed genes and pathways that we have identified in vaccine
344 responders and non-responders pre-vaccination and two weeks post-vaccination are top
345 candidates for early biomarkers of vaccine immunogenicity at week 12. Among the six
346 genes directly linked to MUC1 antibody production at week 12, some have already been
347 identified as diagnostic biomarkers (CEP55, TNFSF14) while the others merit deeper
348 investigation as they hold the potential to enhance our understanding of vaccine
349 response. Overexpression of CEP55 has been observed in numerous cancer cell types,
350 including premalignant lesions of the colon (35), and is a known correlate of poor
351 prognosis (36). Notably, a CEP55 peptide vaccine was proposed for breast and colorectal
352 carcinoma immunotherapy as CEP55 is involved in the PI3K/Akt signaling pathway.
353 TNFSF14, also known as LIGHT, functions as a co-stimulatory factor for the activation of
354 lymphoid cells and modulates T-cell proliferation (37, 38). HLA-DQA2 codes for the alpha
355 chain of the HLA-DQ complex and is primarily involved in antigen presentation (37).
356 Interestingly, HLA-DQ phenotypes have been linked with non-responsiveness to hepatitis
357 B vaccination (39). DDX12P is an m⁶A-associated prognostic pseudogene, correlated
358 with favorable outcomes in patients with head and neck squamous cell carcinoma (40).
359 Furthermore, expression patterns of DDX12P were correlated with anti-tumor response
360 and may regulate immune-involved genes through miRNA targeting. RP11-81H14.2
361 (LINC02384) is a long intergenic non-coding RNA primarily expressed in TH1 cells (41).
362 Little is known about the function of LINC02384; however, it has been proposed to act as
363 a competitive endogenous RNA of IL2RA and IL7R by reducing available shared

364 regulatory miRNAs (42). C22orf29 (also known as RTL10) may have the capacity to
365 induce apoptosis in a BH3 domain-dependent manner, presumably by engaging the Bcl2
366 family regulatory network to modulate the intrinsic apoptotic signaling pathway (43). The
367 identification of known diagnostic biomarkers and immunotherapy targets within our
368 predictive genes lends credence to the graphical models utilized in this study.

369 Given the cancer immunoprevention potential of the MUC1 peptide vaccine response,
370 characterized by a reduction of adenoma recurrence (14), the differentially expressed
371 genes and regulated pathways we identified hold promise as therapeutic targets for
372 vaccine non-responders. While these observations were made on responders and non-
373 responders to the MUC1 vaccine, it is likely that a number of these differentially enriched
374 genes and pathways play a role in other vaccine responses. Many vaccines do not elicit
375 a response in all recipients, such as the yearly flu vaccine which varies in effectiveness
376 between 40% and 60% (44). The selected adjuvant for the MUC1 vaccine, polyICLC,
377 excels at activating dendritic cells to promote type I (innate) immunity (45). Alternative
378 adjuvants may need to be considered for non-responders to the MUC1 peptide
379 adjuvanted with polyICLC. While efforts are often made to improve the vaccine, it also
380 may be important to consider an individual's incoming immune history to respond to the
381 vaccine. Indeed, numerous research studies have demonstrated a correlation between
382 the immune status prior to vaccination and the subsequent antibody response (46, 47).
383 Overall, individuals that responded to the MUC1 vaccine showed a greater readiness in
384 all the immune compartments to present and respond to antigen. The ability to profile
385 individuals as potential responders or non-responders can aid in the selection of those
386 who benefit most from a particular vaccine. At the same time, understanding the barriers

387 to response in non-responders can inform the development of better vaccine designs
388 suitable for specific immune genotypes and phenotypes.

389 **Authors' Disclosures**

390 R.E. Schoen reports support from Freenome, Exact Sciences, and Immunovia during
391 the conduct of the study; in addition, R.E. Schoen has a patent for Anti-MUC1 Binding
392 Agent and Uses Thereof pending. O.J. Finn reports personal fees from PDS Biotech,
393 Invectys, Immodulon, and Ardigen outside the submitted work.

394

395 **Funding**

396 This research was supported by NCI and NHLBI funding to OJF (R35CA210039), PVB
397 (R01HL159805), and MJC (P30CA043703 Sub-Project 9164). VR was supported by a
398 fellowship through the T32CA082084 grant.

399

400 **Acknowledgements**

401 We appreciate the tremendous efforts of the team members that conducted the two
402 clinical trials and provided samples for this study, particularly Lisa Boardman, Marcia
403 Cruz-Correa, Ajay Bansal, David Kastenberg, Chin Hur, Lynda Dzubinski, Sharon
404 Kaufman, Luz M Rodriguez, Ellen Richmond, Asad Umar, Eva Szabo, Andres Salazar,
405 John McKolanis, Pamela Beatty, Reetesh Pai, Aatur Singhi, Camille Jacqueline, Riyue
406 Bao, Brenda Diergaarde, Ryan McMurray, Carrie Strand, Nathan Foster, David Zahrieh,
407 and Paul Limburg. We are also indebted to all the trial participants for their commitment
408 to our cancer prevention mission. We thank the Genomics Core at the Lerner Research
409 Institute of Cleveland Clinic and the Genomics and Applied Functional Genomics Cores
410 at Case Western Reserve University for their technical and analytical support.

411

412

413 **Figure Legends**

414 **Figure 1: Differential gene expression pre- and post-MUC1 vaccination in**
415 **responders and non-responders.** Differentially expressed genes (DEGs) are shown for
416 each time point and contrast in the left column, top 50 DEGs are shown in the right
417 column. Group status is indicated in the row above the heatmap with responders (R) in
418 dark blue, and non-responders (NR) in light blue. Z-scored normalized gene expression
419 for each gene is displayed horizontally across all samples (diverging color scale legend
420 on the upper right of each heatmap). Log₂ fold-change and p values are indicated in the
421 purple and green vertical columns, respectively. Unsupervised clustering of the samples
422 is indicated by the black dendrogram at the top of heatmap, while clustering of the genes
423 is indicated at the far left. Heatmaps showing all DEGs pre-vaccination (Baseline/Week
424 0) (A), top 50 DEGs pre-vaccination (Baseline/Week 0) (B), DEGs at Week 2 post-
425 vaccination (C), top 50 DEGs at Week 2 post-vaccination (D), all genes demonstrating
426 longitudinal changes at Week 2 vs. Week 0 (Delta Wk2-Wk0) (E), top 50 genes
427 demonstrating longitudinal changes at Week 2 vs. Week 0 (Delta Wk2-Wk0) (F) in
428 PBMCs from responders versus non-responders.

429
430 **Figure 2: Differentially expressed T-cell fitness signatures in PBMCs from**
431 **responders and non-responders to MUC1 vaccination is associated with CD4**
432 **frequencies and expression of multiple regulators of T-cell help. (A,B) iCOSL**
433 **signaling pathway-related genes are associated with response to MUC1 vaccination at**
434 **Baseline (A) and Week 2 post-vaccination (B) in MUC1 vaccine responders and non-**
435 **responders. Heatmaps are organized as in Figure 1. (C) Violin plots of CD4+ T-cell**

436 frequencies as determined by flow cytometry. (D-F) Violin plots of CD40L expression on
437 CD4 T-cells (D), CD8 T-cells (E), and the change in ICOS levels on CD8 T-cells (Delta
438 Week 2 vs. Week 0/Baseline) (F) measured by geometric mean fluorescence intensity
439 (MFI).

440

441 **Figure 3: The mTOR signaling pathway is upregulated in enhanced response to**
442 **MUC1 vaccination. (A)** Heatmap showing top differentially enriched pathways from the
443 Hallmark Gene Set (MSigDB) in the PBMCs from high responders (HR) vs. non-
444 responders (NR) at Baseline. Group status is indicated in the row above the heatmap as
445 follows: high responders (HR) - pink, while non-responders (NR) - light blue. Z-scored
446 normalized pathway enrichment log₂ fold-change and p values are displayed as in Figure
447 1. Unsupervised clustering of the samples is indicated at the top of the heatmap, while
448 clustering of the pathways is displayed on the far left. **(B)** Violin plots showing the level of
449 S6 ribosomal protein phosphorylation in the indicated cell subsets (CD4, CD8, CD19/B-
450 cells and CD14/monocytes). **(C)** Violin plots showing the level of AKT1 phosphorylation
451 in the indicated cell subsets (CD4, CD8, CD19/B-cells and CD14/monocytes). For all
452 violin plots, geometric mean fluorescence intensity (MFI) is shown on the y-axis.
453 Responders (R) and non-responders (NR) are designated by dark blue and light blue
454 respectively.

455

456 **Figure 4: B-cell signaling and NFκB signaling signatures are associated with**
457 **response to MUC1 vaccination. (A,B)** Heatmaps showing enrichment of B-Cell
458 Receptor Signaling pathways in the PBMCs from Responders (R) vs. non-responders

459 (NR) at Baseline (A) and high responders (HR) vs. non-responders (NR) at Baseline (B).
460 **(C,D)** Differential gene expression from the CD40 Signaling pathway from PBMCs from
461 R vs. NR at Baseline (C) and Week 2 (D). Heat maps are organized as in Figure 1. **(E)**
462 Violin plots showing expression levels of CD40 and HLA-DR on B-cells (CD19+). **(F)**
463 Violin plots of NF κ B complex p65 subunit phosphorylation in T-cells (CD3+), non-DC/non-
464 B antigen presenting cells (CD11C-HLADR+), and B-cells (CD19+). For violin plots,
465 geometric mean fluorescence intensity (MFI) is shown on the y-axis.

466

467 **Figure 5: Signatures of enhanced antigen presentation are evident in participants**
468 **with an enhanced response to MUC1 vaccination.** Heatmaps showing enrichment of
469 dendritic cell (DC) specific genes in the PBMCs from Responders (R) vs. non-responders
470 (NR) at Baseline (A) and Week 2 post-vaccination (B). Heatmaps are organized as in
471 Figure 1. Violin plots of HLA-DR expression on DCs at Baseline (Week 0) (C), as well
472 relative change in expression of CD86 (D) and CD40 (E) in these cells. For all violin plots,
473 geometric mean fluorescence intensity (MFI) is shown on the y-axis.

474

475 **Figure 6: Graphical models of response from transcriptomic data measured two-**
476 **weeks post-vaccination.** (A) Receiver Operating Characteristic curve of response (≥ 2 -
477 fold increase in IgG) using week 2 transcriptome signature. (B) Correlation of predicted
478 response odds with the magnitude of antibody titer at week 12 (C) Full model showing all
479 neighbors and second neighbors of week 12 antibody titer levels (Week 12 IgG), (D)
480 reduced model showing only direct causes of week 12 antibody titer. Color of edge
481 denotes a positive vs negative correlation, and size denotes edge stability.

482 **Supplemental Material**

483 **Table 1:** Detailed information on antibody panels used for flow cytometric analysis.

484

485 **Supplemental Methods:**

486 **Causal Modeling with MGM-FCI-MAX**

487 A Probabilistic Graphical Model (PGM) represents the joint distribution of variables in a
488 dataset as a graph where each node corresponds to a variable and an edge between two
489 nodes, A and B, corresponds to a conditional dependence between A and B given the
490 rest of the variables in the data (48). PGM's come in two types: directed graphical models
491 rely on additional assumptions to infer cause and effect direction between variables, while
492 undirected graphical models indicate only conditional dependence.

493 MGM-FCI-MAX is a new method to learn a directed model (17). The algorithm
494 begins by inferring an undirected graphical model using the Mixed Graphical Models
495 (MGM) algorithm (16) and then uses FCI-MAX to determine causal direction. MGM
496 models categorical variables as multinomial and continuous variables as Gaussian with
497 a mean given by a linear regression on all other variables. The full joint distribution of the
498 model is given in Equation 1 below. Here, x_s is the sth of p continuous y_j is the jth of q
499 categorical variables. β_{st} is the linear interaction term between two continuous variables,
500 and α_s is the continuous node potential. ρ_{sj} is the edge potential function between
501 continuous and categorical variables, and it takes on one value for each category of the
502 variable y_j . Finally, ϕ_{rj} is the potential function between two categorical variables with a
503 unique value for all combinations of categories of the variables y_r and y_j .

$$504 \quad p(x, y; \theta) \propto \exp \left(\sum_{s=1}^p \sum_{t=1}^p -\frac{1}{2} \beta_{st} x_s x_t + \sum_{s=1}^p \alpha_s x_s + \right. \\ 505 \quad \left. \sum_{s=1}^p \sum_{j=1}^q \rho_{sj}(y_j) x_s + \sum_{j=1}^q \sum_{r=1}^q \phi_{rj}(y_r, y_j) \right) \quad (1)$$

506 The pseudolikelihood approach was used to optimize the model parameters (49).
507 The pseudolikelihood is the product of the conditional distributions of each variable, and

508 it is a consistent estimator of the goodness of fit of the model to the data. To ensure a
509 sparse graph, edges are penalized via the method proposed in (16) with separate penalty
510 parameters for each edge type: (CC = Continuous-Continuous, CD = Continuous-
511 Discrete, DD= Discrete-Discrete) (Equation 2). Here, $\tilde{l}(\theta)$ is the negative-log
512 pseudolikelihood and the rest are penalty terms which ensure a sparse model.

$$513 \operatorname{argmin}_{\theta} \tilde{l}(\theta) + \lambda_{CC} \sum_{\varphi < \omega} |\beta_{\varphi\omega}|_1 + \lambda_{CD} \sum_{\omega, \tau} \|\rho_{\omega\tau}\|_2 + \lambda_{DD} \sum_{\delta < \omega} \|\gamma_{\delta\omega}\|_F \quad (2)$$

514 FCI-MAX is used to determine causal directions using the undirected graph as a
515 starting point. FCI-MAX is an extension of the Fast-Causal Inference (FCI) algorithm (50),
516 which is a sound and complete constraint-based algorithm for learning the causal
517 structure of a set of variables in the presence of confounding variables. FCI uses
518 conditional independence tests to rule out unlikely cause and effect relationships. FCI-
519 MAX improves the accuracy of FCI by performing additional tests to more accurately
520 assign orientations, especially in datasets with small sample sizes. The output of the
521 algorithm is a graphical causal model where there are four possible edges. An edge of
522 the form (“A --> B”) suggests that A is a cause of B and B is not a cause of A. An edge
523 (“A <--> B”) suggests that neither A nor B is a cause of the other, that is, a confounding
524 variable causes both. An edge (“A o--> B”) suggests that if there are no latent variables
525 causing both A and B, then A is a cause of B. Finally, an edge of the form (“A o-o B”)
526 suggests that both endpoints are inconclusive. In high dimensional datasets (small
527 sample size, large number of variables) these algorithms are less accurate in inferring
528 causal orientations as they are in inferring the presence or absence of an edge(17).

529 A likelihood ratio independence test (15) suitable for mixed data was used by FCI-
530 MAX. All three sparsity parameters for MGM ($\lambda_{CC}, \lambda_{CD}, \lambda_{DD}$) were set to the default 0.2 and

531 $\alpha = 0.1$ was used for the independence test threshold for FCI-MAX. MGM-FCI-MAX was
532 run on 100 bootstrap samples of the data, and edges were included in the final model if
533 they appeared in at least 10% of bootstrapped samples.

534

535 **Computational Model Development and Evaluation**

536 LASSO logistic regression (23) was used to develop a prediction model (select
537 genes and infer logistic regression coefficients) for a binary outcome of response defined
538 by the clinical trial endpoint (≥ 2 -fold increase in IgG from baseline to week 12), using
539 transcriptomic data measured two-weeks post-vaccination (Week 2 data). To develop and
540 simultaneously evaluate model predictions, a nested leave-one-out cross validation
541 approach was used. Iteratively, each individual sample is used as an evaluation set with
542 the remaining samples used to learn model parameters. On each training set, a LASSO
543 logistic regression was performed with an internal leave-one-out cross validation to
544 choose the optimal sparsity penalty value (λ). The predictions on the single left-out
545 sample in each round of cross validation were then used for downstream analysis.

546 The Receiver Operator Characteristic (ROC) curve was calculated, and predictive
547 accuracy of the model was measured using the area under the curve (AUC) of response
548 vs. non-response, as well as sensitivity and specificity of predicted probabilities. Feature
549 stability was measured to ensure that models remained similar across different cross-
550 validation iterations.

551 MGM-FCI-MAX was used to infer the variables directly linked to response, using
552 clinical data (age, sex, and BMI) and those genes selected by LASSO in the week 2
553 transcriptomic data in at least one of the ten folds. LASSO logistic regression was used

554 to build a predictive model of response in each cross-validation fold. All statistical analysis
555 was performed in R.
556

557 REFERENCES

- 558 1. Zitvogel L, Perreault C, Finn OJ, Kroemer G. Beneficial autoimmunity improves
559 cancer prognosis. *Nat Rev Clin Oncol*. 2021;18(9):591-602.
- 560 2. Jacqueline C, Finn OJ. Antibodies specific for disease-associated antigens
561 (DAA) expressed in non-malignant diseases reveal potential new tumor-associated
562 antigens (TAA) for immunotherapy or immunoprevention. *Semin Immunol*.
563 2020;47:101394.
- 564 3. Finn OJ, Rammensee HG. Is It Possible to Develop Cancer Vaccines to
565 Neoantigens, What Are the Major Challenges, and How Can These Be Overcome?
566 Neoantigens: Nothing New in Spite of the Name. *Cold Spring Harb Perspect Biol*.
567 2018;10(11).
- 568 4. Gnjatic S, Bronte V, Brunet LR, Butler MO, Disis ML, Galon J, et al. Identifying
569 baseline immune-related biomarkers to predict clinical outcome of immunotherapy. *J*
570 *Immunother Cancer*. 2017;5:44.
- 571 5. Liu J, Fu M, Wang M, Wan D, Wei Y, Wei X. Cancer vaccines as promising
572 immuno-therapeutics: platforms and current progress. *J Hematol Oncol*. 2022;15(1):28.
- 573 6. Gordon B, Gadi VK. The Role of the Tumor Microenvironment in Developing
574 Successful Therapeutic and Secondary Prophylactic Breast Cancer Vaccines. *Vaccines*
575 (Basel). 2020;8(3).
- 576 7. Kimura T, McKolanis JR, Dzubinski LA, Islam K, Potter DM, Salazar AM, et al.
577 MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer
578 immunoprevention feasibility study. *Cancer Prev Res (Phila)*. 2013;6(1):18-26.
- 579 8. Ramanathan RK, Lee KM, McKolanis J, Hitbold E, Schraut W, Moser AJ, et al.
580 Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with
581 SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. *Cancer Immunol*
582 *Immunother*. 2005;54(3):254-64.
- 583 9. Pantuck AJ, van Ophoven A, Gitlitz BJ, Tso CL, Acres B, Squiban P, et al. Phase
584 I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding
585 MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer. *J*
586 *Immunother*. 2004;27(3):240-53.
- 587 10. Bartsch R, Singer CF, Pfeiler G, Hubalek M, Stoeger H, Pichler A, et al.
588 Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide
589 and docetaxel: sequencing results from ABCSG-34. *Br J Cancer*. 2021;124(11):1795-
590 802.
- 591 11. Schimanski CC, Kasper S, Hegewisch-Becker S, Schroder J, Overkamp F,
592 Kullmann F, et al. Adjuvant MUC vaccination with tecemotide after resection of
593 colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter
594 AIO phase II trial (LICC). *Oncoimmunology*. 2020;9(1):1806680.
- 595 12. Ma P, Beatty PL, McKolanis J, Brand R, Schoen RE, Finn OJ. Circulating
596 Myeloid Derived Suppressor Cells (MDSC) That Accumulate in Premalignancy Share
597 Phenotypic and Functional Characteristics With MDSC in Cancer. *Front Immunol*.
598 2019;10:1401.
- 599 13. Lohmueller JJ, Sato S, Popova L, Chu IM, Tucker MA, Barberena R, et al.
600 Antibodies elicited by the first non-viral prophylactic cancer vaccine show tumor-
601 specificity and immunotherapeutic potential. *Sci Rep*. 2016;6:31740.

- 602 14. Schoen RE, Boardman LA, Cruz-Correa M, Bansal A, Kastenber D, Hur C, et
603 al. Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for
604 Prevention of Recurrent Colorectal Adenoma. *Clin Cancer Res.* 2023;29(9):1678-88.
- 605 15. Sedgewick AJ, Buschur K, Shi I, Ramsey JD, Raghu VK, Manatakis DV, et al.
606 Mixed graphical models for integrative causal analysis with application to chronic lung
607 disease diagnosis and prognosis. *Bioinformatics.* 2019;35(7):1204-12.
- 608 16. Sedgewick AJ, Shi I, Donovan RM, Benos PV. Learning mixed graphical models
609 with separate sparsity parameters and stability-based model selection. *BMC*
610 *Bioinformatics.* 2016;17 Suppl 5:175.
- 611 17. Raghu VK, Ramsey JD, Morris A, Manatakis DV, Sprites P, Chrysanthis PK, et
612 al. Comparison of strategies for scalable causal discovery of latent variable models from
613 mixed data. *Int J Data Sci Anal.* 2018;6(1):33-45.
- 614 18. Jiang H, Lei R, Ding SW, Zhu S. Skewer: a fast and accurate adapter trimmer for
615 next-generation sequencing paired-end reads. *BMC Bioinformatics.* 2014;15:182.
- 616 19. Kim D, Langmead B, Salzberg SL. HISAT: a fast spliced aligner with low memory
617 requirements. *Nat Methods.* 2015;12(4):357-60.
- 618 20. Yang J, Ding X, Sun X, Tsang SY, Xue H. SAMSVM: A tool for misalignment
619 filtration of SAM-format sequences with support vector machine. *J Bioinform Comput*
620 *Biol.* 2015;13(6):1550025.
- 621 21. Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program
622 for assigning sequence reads to genomic features. *Bioinformatics.* 2014;30(7):923-30.
- 623 22. Hanzelmann S, Castelo R, Guinney J. GSEA: gene set variation analysis for
624 microarray and RNA-seq data. *BMC Bioinformatics.* 2013;14:7.
- 625 23. Tibshirani R. Regression shrinkage and selection via the lasso. *Journal of the*
626 *Royal Statistical Society: Series B (Methodological).* 1996;58(1):267-88.
- 627 24. Wang XX, Fu L, Li X, Wu X, Zhu Z, Fu L, Dong JT. Somatic mutations of the
628 mixed-lineage leukemia 3 (MLL3) gene in primary breast cancers. *Pathol Oncol Res.*
629 2011;17(2):429-33.
- 630 25. Wysocka J, Myers MP, Laherty CD, Eisenman RN, Herr W. Human Sin3
631 deacetylase and trithorax-related Set1/Ash2 histone H3-K4 methyltransferase are
632 tethered together selectively by the cell-proliferation factor HCF-1. *Genes Dev.*
633 2003;17(7):896-911.
- 634 26. Shen K, Valenstein ML, Gu X, Sabatini DM. Arg-78 of Npr12 catalyzes GATOR1-
635 stimulated GTP hydrolysis by the Rag GTPases. *J Biol Chem.* 2019;294(8):2970-5.
- 636 27. Pudakalakatti S, Titus M, Enriquez JS, Ramachandran S, Zacharias NM,
637 Shureiqi I, et al. Identifying the Metabolic Signatures of PPARD-Overexpressing Gastric
638 Tumors. *Int J Mol Sci.* 2022;23(3).
- 639 28. Padua D, Pinto DF, Figueira P, Pereira CF, Almeida R, Mesquita P. HMGA1 Has
640 Predictive Value in Response to Chemotherapy in Gastric Cancer. *Curr Oncol.*
641 2021;29(1):56-67.
- 642 29. Lin Y, Lin L, Fu F, Wang C, Hu A, Xie J, et al. Quantitative proteomics reveals
643 stage-specific protein regulation of triple negative breast cancer. *Breast Cancer Res*
644 *Treat.* 2021;185(1):39-52.
- 645 30. Terribas E, Fernandez M, Mazuelas H, Fernandez-Rodriguez J, Biayna J, Blanco
646 I, et al. KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for
647 malignant peripheral nerve sheath tumors. *Neurooncol Adv.* 2020;2(Suppl 1):i62-i74.

- 648 31. Han J, Xie R, Yang Y, Chen D, Liu L, Wu J, Li S. CENPA is one of the potential
649 key genes associated with the proliferation and prognosis of ovarian cancer based on
650 integrated bioinformatics analysis and regulated by MYBL2. *Transl Cancer Res.*
651 2021;10(9):4076-86.
- 652 32. Feng Y, Li F, Yan J, Guo X, Wang F, Shi H, et al. Pan-cancer analysis and
653 experiments with cell lines reveal that the slightly elevated expression of DLGAP5 is
654 involved in clear cell renal cell carcinoma progression. *Life Sci.* 2021;287:120056.
- 655 33. Ueda Y, Ooshio I, Fusamae Y, Kitae K, Kawaguchi M, Jingushi K, et al. AlkB
656 homolog 3-mediated tRNA demethylation promotes protein synthesis in cancer cells.
657 *Sci Rep.* 2017;7:42271.
- 658 34. Nakaya HI, Wrammert J, Lee EK, Racioppi L, Marie-Kunze S, Haining WN, et al.
659 Systems biology of vaccination for seasonal influenza in humans. *Nat Immunol.*
660 2011;12(8):786-95.
- 661 35. Sakai M, Shimokawa T, Kobayashi T, Matsushima S, Yamada Y, Nakamura Y,
662 Furukawa Y. Elevated expression of C10orf3 (chromosome 10 open reading frame 3) is
663 involved in the growth of human colon tumor. *Oncogene.* 2006;25(3):480-6.
- 664 36. Jeffery J, Sinha D, Srihari S, Kalimutho M, Khanna KK. Beyond cytokinesis: the
665 emerging roles of CEP55 in tumorigenesis. *Oncogene.* 2016;35(6):683-90.
- 666 37. Stelzer G, Rosen N, Plaschkes I, Zimmerman S, Twik M, Fishilevich S, et al. The
667 GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses.
668 *Curr Protoc Bioinformatics.* 2016;54:1 30 1-1 3.
- 669 38. Capece D, Verzella D, Fischietti M, Zazzeroni F, Alesse E. Targeting
670 costimulatory molecules to improve antitumor immunity. *J Biomed Biotechnol.*
671 2012;2012:926321.
- 672 39. Singh R, Kaul R, Kaul A, Khan K. A comparative review of HLA associations with
673 hepatitis B and C viral infections across global populations. *World J Gastroenterol.*
674 2007;13(12):1770-87.
- 675 40. Tan L, Qin Y, Xie R, Xia T, Duan X, Peng L, et al. N6-methyladenosine-
676 associated prognostic pseudogenes contribute to predicting immunotherapy benefits
677 and therapeutic agents in head and neck squamous cell carcinoma. *Theranostics.*
678 2022;12(17):7267-88.
- 679 41. Spurlock CF, 3rd, Tossberg JT, Guo Y, Collier SP, Crooke PS, 3rd, Aune TM.
680 Expression and functions of long noncoding RNAs during human T helper cell
681 differentiation. *Nat Commun.* 2015;6:6932.
- 682 42. Zhang C, Dang D, Cong L, Sun H, Cong X. Pivotal factors associated with the
683 immunosuppressive tumor microenvironment and melanoma metastasis. *Cancer Med.*
684 2021;10(14):4710-20.
- 685 43. Zhang X, Weng C, Li Y, Wang X, Jiang C, Li X, et al. Human Bop is a novel BH3-
686 only member of the Bcl-2 protein family. *Protein Cell.* 2012;3(10):790-801.
- 687 44. Smith DJ, Forrest S, Ackley DH, Perelson AS. Variable efficacy of repeated
688 annual influenza vaccination. *Proc Natl Acad Sci U S A.* 1999;96(24):14001-6.
- 689 45. Caskey M, Lefebvre F, Filali-Mouhim A, Cameron MJ, Goulet JP, Haddad EK, et
690 al. Synthetic double-stranded RNA induces innate immune responses similar to a live
691 viral vaccine in humans. *J Exp Med.* 2011;208(12):2357-66.
- 692 46. Team H-CSP, Consortium H-I. Multicohort analysis reveals baseline
693 transcriptional predictors of influenza vaccination responses. *Sci Immunol.* 2017;2(14).

- 694 47. Fourati S, Tomalin LE, Mule MP, Chawla DG, Gerritsen B, Rychkov D, et al. Pan-
695 vaccine analysis reveals innate immune endotypes predictive of antibody responses to
696 vaccination. *Nat Immunol.* 2022;23(12):1777-87.
- 697 48. Koller D, Friedman, N. *Probabilistic graphical models: principles and techniques:*
698 *MIT press;* 2009.
- 699 49. Lee JD, Hastie TJ. Learning the Structure of Mixed Graphical Models. *J Comput*
700 *Graph Stat.* 2015;24(1):230-53.
- 701 50. Spirtes P, Meek C, Richardson T, editors. *Causal inference in the presence of*
702 *latent variables and selection bias. Proceedings of the Eleventh conference on*
703 *Uncertainty in artificial intelligence;* 1995: Morgan Kaufmann Publishers Inc.
704





Figure 2



A **Top Hallmark Pathways at Baseline**
High-Responder vs. Non-Responder






Figure 4 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).




Figure 5







Figure 6



Supplemental Table 1

Panel 1: Innate Phenotyping

Company	Cat #	Antibody	Color
BD	560114	STAT3 (pY705)	PerCP-Cy5.5
BD	558421	anti-NF-κB p65 (pS529)	A488
BD	563931	CD152/CTLA4	BV786
Biologend	305440	CD86	BV711
BD	743008	CD275/ICOSLG	BV650
BD	563929	CD11c	BV605
Invitrogen	L34957	Live/Dead	Amcyan
Biologend	318340	CD56	BV510
BD	558122	CD16	PB
BD	564303	CD19	BUV737
BD	563546	CD3	BUV395
BD	335796	HLA-DR	APC Cy7
BD	557923	CD14	A700
BD	612593	Anti-ERK1/2 (pT202/pY204)	APC
Biologend	334321	CD40	PE-Cy7
BD	563601	BCL-2	PE-CF594
BD	555388	CD11b	PE

Panel 2: MTOR Signaling

Company	Cat #	Antibody (Clone)	Color
BD	338426	CD16	PerCP-Cy5.5
BD	560048	anti-Akt1 (PKBa/Akt)	FITC
BD	564058	CD56	BV786
BD	563677	CD8	BV711
Biologend	304135	CD45RA	BV650
Invitrogen	Q10008	CD4	Q.605
Invitrogen	L34957	Live/Dead	Amcyan
Biologend	302242	CD19	BV510
BD	561457	pS6 (S235/S236)	V450
BD	564444	CD14	BUV737
BD	565885	Anti-ICOS (CD278)	BUV395
BD	563588	Anti-Human CD154 (CD40L)	APCeFluor780
BD	557943	CD3	A700
BD	560432	Anti-S6 pS240	A647
BD	562321	CD19	PE-CF594
BD	560684	Anti-Human CD28	PE-Cy7
BD	560285	p4E-BP1 (T36/46)	PE